Cydan

@Cydanco

Cydan, an orphan drug accelerator dedicated to creating therapies that improve the lives of patients living with rare genetic diseases.

Cambridge, MA
Vrijeme pridruživanja: veljača 2015.

Medijski sadržaj

  1. 14. sij

    Proud to participate and sponsor Rare In the Square. Thanks to Global Genes and the other sponsors for bringing this important event to

  2. 13. sij

    Cydan is excited to support Global Genes at the Rare in the Square event at

  3. 1. lis 2019.

    We're proud to have attended the Energy Ball! Pictured here is Ronald J. Bartek, President/Director/Co-Founder of FARA, and James McArthur, Founder and President of Cydan.

  4. 19. ruj 2019.

    We're excited to be participating in the Global Genes Rare Patient Advocacy Summit. If you're attending, swing by Imran's panel - Friday September 20 at 1:00

  5. 26. kol 2019.

    James and Ryan had a great time this weekend at Cycle 4 CMT, a fundraising ride for Charcot-Marie-Tooth, or CMT. If you’re interested in helping, consider donating at

  6. 23. kol 2019.

    This Saturday we’ll be riding for a good cause and fundraising to find a cure for people with Charcot-Marie-Tooth, or CMT, a progressive neurological disease. If you’re interested in helping, consider donating at

  7. 26. srp 2019.

    Cydan is excited to participate at the annual HNRNPH2 family meeting. Great scientific progress and increase in rate of patient identification => 100 patients soon!

  8. 11. srp 2019.

    Our Co-Founder and President R&D, James McArthur, has been a part of the FARA board of directors and scientific advisory board for the last several years as part of our commitment to help advance meaningful treatments for patients with rare genetic diseases.

  9. 13. lip 2019.

    If you're attending the today, 's Imran Babar, PhD, will be part of a panel discussion during the Partnering & Investment track at 1:45 p.m. Under its collaborative model, Cydan has launched three new companies focused on rare disease.

  10. 11. lip 2019.

    's Imran Babar, PhD will be in Boston at the tomorrow to participate in a panel discussion on funding rare disease therapies. Cydan works with leading investors in to accelerate science to medicine.

  11. 6. lip 2019.

    Our team is wrapping up a great week at . Thank you to for connecting the best in the industry and helping 's efforts to uncover compelling new science and promising drug candidates in .

  12. 4. lip 2019.

    We’re hoping to help a friend. Ranjana has been on dialysis and needs a new kidney. Despite her disease, she’s graduated both high school and college. Let’s help this fighter find a new kidney. Please spread the word.

  13. 4. lip 2019.

    engages with academic and government laboratories, and small biotechnology and pharmaceutical companies worldwide to pinpoint opportunities in the development of new therapies for .

  14. 3. lip 2019.

    Happy to be in Philadelphia to network with 17,000+ colleagues at ! is a champion of rare disease therapies. Let's connect to talk about your scientific concept, program or asset!

  15. 30. svi 2019.

    Cydan is deeply invested in improving the lives of patients with rare diseases like Friedreich's Ataxia. Check out our latest 'Rare Views' blog post to learn about our relationship with and our unique approach to patient care.

  16. 15. svi 2019.

    Excited to support Entrepreneurship ⁦⁩ - 30 years getting better every year!

  17. 9. svi 2019.

    We're at talking this week. Our work starts with a compelling scientific idea or promising drug candidate from academia and industry. Pleased to make new connections and learn about exciting new research!

  18. 8. svi 2019.

    This week, is at 's RE(ACT) Congress America. We're invested in the advancement of rare and orphan disease research and are excited to make connections and immerse ourselves in cutting-edge research.

  19. 24. tra 2019.

    The need for treatments for patients facing rare genetic diseases is astounding. Of the more than 7,000 rare diseases, there are only 400 treatments available. We can do better.

  20. 16. tra 2019.

    De-risking, the final stage of our collaborative model, is designed to yield a pre-investigational new drug (IND) or IND-enabled asset considered ready for funding and to launch a new company to bring this orphan drug candidate to patients.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·